{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:59Z","timestamp":1792985759264,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004769","name":"Universita di Pavia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007365","name":"Foundation IRCCS Polyclinic San Matteo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104857","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:05:26Z","timestamp":1752768326000},"page":"104857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Novel androgen receptor inhibitors in prostate cancer: What do we know so far?"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8475-719X","authenticated-orcid":false,"given":"Francesca","family":"Rifaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Sporeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Figini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Lawrence John","family":"Naspro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Secondino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chiellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.critrevonc.2025.104857_bib1","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"166","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00498254.2012.721022","article-title":"A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects","volume":"43","author":"Acharya","year":"2013","journal-title":"Xenobiotica"},{"issue":"10398","key":"10.1016\/j.critrevonc.2025.104857_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"17_","key":"10.1016\/j.critrevonc.2025.104857_bib4","first-page":"43","article-title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","author":"Agarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104857_bib5","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104857_bib6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.euo.2024.04.014","article-title":"Combination of abiraterone acetate, prostate bed radiotherapy, and luteinizing hormone-releasing hormone agonists in biochemically relapsing patients after prostatectomy (CARLHA): a phase 2 clinical trial","volume":"8","author":"Ah-Thiane","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2025.104857_bib8","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104857_bib9","unstructured":"Attard G., Murphy L., Clarke N.W., Cross W., Jones R.J., Parker C.C., et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet (London, England) [Internet]. 2022 Jan 29 [cited 2025 Jul 6];399(10323):447\u2013460. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34953525\/."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104857_bib10","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib11","article-title":"Overcoming mutation-based resistance to antiandrogens with rational drug design","volume":"2","author":"Balbas","year":"2013","journal-title":"Elife [Internet]"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PPO.0000000000000428","article-title":"Next generation of androgen deprivation therapy combined with radiotherapy for N0 M0 prostate cancer","volume":"26","author":"Barata","year":"2020","journal-title":"Cancer J. [Internet]"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104857_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104857_bib16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/pcmedi\/pbab003","article-title":"Neuroendocrine cells of the prostate: histology, biological functions, and molecular mechanisms","volume":"4","author":"Butler","year":"2021","journal-title":"Precis Clin. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104857_bib20","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104857_bib21","unstructured":"Compound Summary Darolutamide. 5.9.2023]; \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Darolutamide\u3009. Accessed 5 Sept 2022."},{"key":"10.1016\/j.critrevonc.2025.104857_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2018.04.083","article-title":"Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens","volume":"200","author":"Crawford","year":"2018","journal-title":"J. Urol."},{"issue":"3 Pt 1","key":"10.1016\/j.critrevonc.2025.104857_bib24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2007.05.044","article-title":"Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers","volume":"178","author":"Culine","year":"2007","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104857_bib25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104857_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104857_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123020","article-title":"Pharmacological optimization of PSMA-based radioligand therapy","volume":"10","author":"van der Gaag","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104857_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajur.2018.11.007","article-title":"Diagnosis of prostate cancer","volume":"6","author":"Descotes","year":"2019","journal-title":"Asian J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104857_bib30","unstructured":"EMA. European Public Assesment Report (EPAR): Nubeqa (darolutamide) Amsterdam: EMA, 2020."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104857_bib32","unstructured":"ERLEADATM (apalutamide) prescribing information. 2018. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/21095\u3009 1s000lbl.pdf. (Accessed 11 Jan 2019)."},{"key":"10.1016\/j.critrevonc.2025.104857_bib33","unstructured":"European Medicines Agency (EMA) [Internet]. [cited 2025 Jul 6]. Available from: https:\/\/www.ema.europa.eu\/En\/News\/Ema-Annual-Report-2018-Published."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104857_bib34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104857_bib35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/JU.0000000000000443","article-title":"Re: darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"202","author":"Fizazi","year":"2019","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104857_bib38","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/annonc\/mdr004","article-title":"Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial","volume":"22","author":"Fl\u00e9chon","year":"2011","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104857_bib39","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104857_bib40","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/pros.23445","article-title":"Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells","volume":"78","author":"Ghashghaei","year":"2018","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104857_bib42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","article-title":"Clinical pharmacokinetic studies of enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104857_bib43","doi-asserted-by":"crossref","unstructured":"Gillessen S., Choudhury A., Saad F., Gallardo E., Soares A., Loriot Y., et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333\/PEACE-3. Ann Oncol [Internet]. 2024 Sep 1 [cited 2025 Jul 6];35:S1254. Available from: \u3008https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753424038870\u3009.","DOI":"10.1016\/j.annonc.2024.08.2307"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94707-2","article-title":"Conformational dynamics of androgen receptors bound to agonists and antagonists","volume":"11","author":"Gim","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104857_bib45","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov."},{"issue":"37","key":"10.1016\/j.critrevonc.2025.104857_bib46","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.2217\/fon-2022-0776","article-title":"KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer","volume":"18","author":"Gratzke","year":"2023","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.5534\/wjmh.220200","article-title":"Systemic therapies for metastatic castration-resistant prostate cancer: an updated review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J. Mens. Health"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104857_bib49","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104857_bib50","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104857_bib51","doi-asserted-by":"crossref","unstructured":"Jacob A., Raj R., Allison D.B., Myint Z.W. Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. Cancers (Basel) [Internet]. 2021 Nov 1 [cited 2025 Jul 6];13(21). Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/34771580\/\u3009.","DOI":"10.3390\/cancers13215417"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104857_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104857_bib54","series-title":"Bioavailability study of 3 tablet formulations vs. capsule formulation of JNJ-56021927 in fasting healthy male participants [ClinicalTrials.gov identifer","author":"Janssen Research & Development","year":"2016"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/acs.jcim.8b00796","article-title":"Communication between the ligand-binding pocket and the activation function-2 domain of androgen receptor revealed by molecular dynamics simulations","volume":"59","author":"Jin","year":"2019","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.critrevonc.2025.104857_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5653862","article-title":"Prostate cancer: epigenetic alterations, risk factors, and therapy","volume":"2016","author":"Kgatle","year":"2016","journal-title":"Prostate Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.1209","article-title":"PSMAddition: phase 3 trial of [177lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic hormone-sensitive prostate cancer","volume":"120","author":"Kim","year":"2025","journal-title":"Int. J. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pros.24664","article-title":"Diagnosis and management of neuroendocrine prostate cancer","volume":"84","author":"de Kouchkovsky","year":"2024","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11523-023-00984-4","article-title":"Darolutamide: a review in metastatic hormone-sensitive prostate cancer","volume":"18","author":"Lee","year":"2023","journal-title":"Target Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104857_bib60","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.eururo.2020.02.025","article-title":"Association between second progression-free survival (PFS2) and overall survival in metastatic castration-resistant prostate cancer","volume":"77","author":"Lorente","year":"2020","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib61","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/annonc\/mdn694","article-title":"Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features","volume":"20","author":"Loriot","year":"2009","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104857_bib62","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jcph.253","article-title":"Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment","volume":"54","author":"Marbury","year":"2014","journal-title":"J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib63","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","article-title":"Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study","volume":"69","author":"Massard","year":"2016","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","article-title":"The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and gleason score","volume":"74","author":"Miller","year":"2018","journal-title":"Eur. Urol. [Internet]"},{"key":"10.1016\/j.critrevonc.2025.104857_bib65","unstructured":"Pratik K. Mutha, Robert L. Sainburg, K. Y. H & John R..Giudicessi BMJA. \u57fa\u56e0\u7684\u6539\u53d8. Bone 23, 1\u20137, 2008, 2013."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104857_bib67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104857_bib68","unstructured":"Nubeqa | European Medicines Agency (EMA) [Internet]. [cited 2025 Jul 8]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nubeqa\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104857_bib69","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.21037\/tau-20-1131","article-title":"Narrative review of challenges in the management of advanced neuroendocrine prostate cancer","volume":"10","author":"Okasho","year":"2021","journal-title":"Transl. Androl. Urol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104857_bib70","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","article-title":"Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate","volume":"20","author":"Papandreou","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib71","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41391-021-00465-7","article-title":"Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial","volume":"25","author":"Penson","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40262-019-00808-7","article-title":"Population pharmacokinetics of apalutamide and its active metabolite n-desmethyl-apalutamide in healthy and castration-resistant prostate cancer subjects","volume":"59","author":"P\u00e9rez-Ruixo","year":"2020","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib73","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0360-3016(01)01750-3","article-title":"Lack of prostate cancer radiosensitization by androgen deprivation","volume":"51","author":"Pollack","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer-a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104857_bib75","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The effect of F877L and T878A mutations on androgen receptor response to enzalutamide","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104857_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114103","article-title":"Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial","volume":"205","author":"Rescigno","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib77","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104857_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-med-062117-073027","article-title":"Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications","volume":"70","author":"Rowe","year":"2019","journal-title":"Annu Rev. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104857_bib79","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104857_bib80","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib81","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","article-title":"Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN","volume":"81","author":"Saad","year":"2022","journal-title":"Eur. Urol."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104857_bib82","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib83","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study","volume":"8","author":"Santoni","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104857_bib84","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104857_bib86","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104857_bib87","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104857_bib88","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11523-020-00779-x","article-title":"Darolutamide: a review in non-metastatic castration-resistant prostate cancer","volume":"15","author":"Scott","year":"2020","journal-title":"Target Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104857_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Mol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib90","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell [Internet]"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41416-023-02492-8","article-title":"Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN","volume":"130","author":"Shen","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104857_bib92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol.]"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib93","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JU.0000000000004163","article-title":"Apalutamide for high-risk localized prostate cancer following radical prostatectomy (Apa-RP)","volume":"212","author":"Shore","year":"2024","journal-title":"J. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104857_bib94","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104857_bib95","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104857_bib96","unstructured":"Study Details | Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants | ClinicalTrials.gov [Internet]. [cited 2025 Jul 6]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02160756\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104857_bib97","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ijc.32242","article-title":"Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models","volume":"145","author":"Sugawara","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib98","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-0868-1","article-title":"The emerging role of local therapy in metastatic prostate cancer","volume":"22","author":"Sundahl","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"10295","key":"10.1016\/j.critrevonc.2025.104857_bib99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104857_bib100","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104857_bib101","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104857_bib102","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.21873\/anticanres.17069","article-title":"Efficacy of combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer with bone metastases","volume":"44","author":"Wakita","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2025.104857_bib103","unstructured":"Xtandi | European Medicines Agency. (n.d.). Retrieved March 2024, from \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi\u3009."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104857_bib104","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00000478-200606000-00005","article-title":"Small cell carcinoma of the prostate: an immunohistochemical study","volume":"30","author":"Yao","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104857_bib105","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/1878-0261.13641","article-title":"TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer","volume":"18","author":"Yoshida","year":"2024","journal-title":"Mol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104857_bib106","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/cpdd.1001","article-title":"Pharmacokinetics and use-testing of apalutamide prepared in aqueous food vehicles for alternative administration","volume":"10","author":"Yu","year":"2021","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104857_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus Olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 Cohort A study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur. Urol. [Internet]"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104857_bib108","article-title":"Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): a single-arm phase 2 study","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104857_bib109","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-021-01078-y","article-title":"Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment","volume":"61","author":"Zurth","year":"2022","journal-title":"Clin. Pharm."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:26:02Z","timestamp":1792985162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":109,"alternative-id":["S1040842825002458"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104857","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel androgen receptor inhibitors in prostate cancer: What do we know so far?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104857"}}